International Journal of Medical Science and Clinical Research Studies

ISSN(print): 2767-8326, ISSN(online): 2767-8342

Volume 04 Issue 05 May 2024

Page No: 982-985

DOI: https://doi.org/10.47191/ijmscrs/v4-i05-32, Impact Factor: 7.949

Arrhythmogenic Right Ventricular Dysplasia: A Comprehensive Review of Pathophysiology, Diagnosis, and Management Strategies

Gabriela Rojas Cruz[1], Ricardo Daniel Flores Altamirano[2], Omar Alejandro Leal Avalos[3], Laura Leticia Torres Martínez[4], Joanna Paola Morales Gloria[5]

[1,2,3,4,5] Departamento de Medicina Interna. Universidad Nacional Autónoma de México (UNAM). Hospital General Xoco. Ciudad de México, México

ABSTRACT

Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a rare inherited heart disorder characterized by fibrofatty replacement of the right ventricular myocardium, leading to ventricular arrhythmias and an increased risk of sudden cardiac death. This review aims to provide a comprehensive overview of ARVD, including its pathophysiology, clinical manifestations, diagnostic criteria, and management strategies. The pathogenesis of ARVD involves genetic mutations affecting proteins of the cardiac desmosome, leading to myocardial cell death and fibrofatty replacement. Clinical presentation varies widely, ranging from asymptomatic individuals to those with palpitations, syncope, or sudden cardiac arrest. Diagnosis is challenging and relies on a combination of clinical, electrocardiographic, imaging, and histopathologic findings. Management involves risk stratification for sudden cardiac death, lifestyle modifications, antiarrhythmic medications, and, in select cases, implantable cardioverter-defibrillator placement or catheter ablation.

KEYWORDS: arrhythmogenic, ventricular, heart, fibrofatty

ARTICLE DETAILS

Published On:
28 May 2024

Available on:
https://ijmscr.org/

INTRODUCTION

Arrhythmogenic Right Ventricular Dysplasia (ARVD), also known as Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC), is a rare but potentially life-threatening condition characterized by the progressive replacement of the right ventricular myocardium with fibrous and fatty tissue. This pathological remodeling predisposes individuals to ventricular arrhythmias, which can lead to syncope, heart failure, or sudden cardiac death, particularly in young athletes. ARVD predominantly affects the right ventricle but can also involve the left ventricle and interventricular septum in some cases. The exact prevalence of ARVD is unknown, but it is estimated to affect approximately 1 in 1,000 to 1 in 5,000 individuals worldwide. ARVD is considered a heritable condition, with mutations in genes encoding proteins of the cardiac desmosome identified as the underlying cause in many cases. However, the full spectrum of genetic and environmental factors contributing to ARVD remains incompletely understood. This review aims to provide a comprehensive overview of ARVD, focusing on its pathophysiology, clinical manifestations, diagnostic criteria, and current management strategies.1,2,3

Epidemiology of Arrhythmogenic Right Ventricular Dysplasia (ARVD):

Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a rare cardiac disorder characterized by fibrofatty replacement of the right ventricular myocardium. The exact prevalence of ARVD is not well established due to its variable and often asymptomatic presentation, but it is estimated to affect approximately 1 in 1,000 to 1 in 5,000 individuals worldwide. ARVD most commonly presents in young adults, with a mean age at diagnosis of 31 years. However, the age of onset can vary widely, ranging from adolescence to late adulthood.4,5

ARVD exhibits geographic and ethnic variations in prevalence, with higher rates reported in certain populations, such as individuals of Italian and Greek descent. Male predominance has also been observed, with males accounting for approximately 60-70% of affected individuals.4,5

Family history is a significant risk factor for ARVD, as the condition is inherited in an autosomal dominant pattern with variable penetrance. Genetic studies have identified

mutations in several genes encoding proteins of the cardiac desmosome, including desmoplakin, plakophilin-2, and desmoglein-2, among others, as the underlying cause of ARVD in up to 50% of cases.4,5

The clinical presentation of ARVD is highly variable, ranging from asymptomatic individuals to those with ventricular arrhythmias, syncope, or sudden cardiac death. The risk of sudden cardiac death in individuals with ARVD is estimated to be approximately 2-4% per year.4,5

In conclusion, ARVD is a rare but potentially life-threatening cardiac disorder with variable prevalence and clinical presentation. Further research is needed to better understand the genetic and environmental factors contributing to ARVD and to improve its diagnosis and management.4,5

CLINICAL MANIFESTATIONS

Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a rare inherited heart disorder characterized by fibrofatty replacement of the right ventricular myocardium, leading to ventricular arrhythmias and an increased risk of sudden cardiac death. The clinical manifestations of ARVD can vary widely among affected individuals and may include:

Palpitations: Irregular or rapid heartbeat sensations, often due to ventricular arrhythmias such as premature ventricular contractions (PVCs) or ventricular tachycardia (VT).4,5

Syncope: Sudden loss of consciousness, which can occur due to arrhythmias that result in inadequate blood flow to the brain.4,5

Sudden Cardiac Arrest: Abrupt loss of heart function, leading to loss of consciousness and, if not treated immediately, death.4,5

Heart Failure: In some cases, ARVD can progress to heart failure, a condition in which the heart is unable to pump enough blood to meet the body's needs.6,7

Other clinical features of ARVD may include:

Epsilon waves: A characteristic feature seen on electrocardiogram (ECG) indicating delayed activation of the right ventricle.8,9

T-wave inversion: Inverted T-waves in the precordial leads of the ECG, a common finding in ARVD.8,9

Right ventricular enlargement: Enlargement of the right ventricle, which may be detected on imaging studies such as echocardiography or cardiac magnetic resonance imaging (MRI).

Ventricular aneurysms: Localized bulging or outpouchings of the right ventricular wall, which can be seen on imaging studies.8,9

It is important to note that the clinical presentation of ARVD can be highly variable, and some individuals may remain asymptomatic for many years despite having the characteristic pathological changes in the heart. Therefore, a high index of suspicion is required to diagnose ARVD, especially in individuals with a family history of the condition or unexplained ventricular arrhythmias.8,9

DIAGNOSIS

Diagnosing Arrhythmogenic Right Ventricular Dysplasia (ARVD) can be challenging due to its variable clinical presentation and the absence of a single definitive diagnostic test. The diagnosis of ARVD is typically based on a combination of clinical, electrocardiographic, imaging, and histopathologic findings. The following diagnostic criteria are commonly used:

Clinical Criteria:

Family history of ARVD or sudden cardiac death at a young age.

Ventricular arrhythmias, such as ventricular tachycardia or frequent premature ventricular contractions.10,11

Symptoms such as palpitations, syncope, or cardiac arrest.12

Electrocardiographic (ECG) Findings:

Epsilon waves: Small positive deflections at the end of the QRS complex, indicating delayed activation of the right ventricle.12

T-wave inversion in the right precordial leads (V1-V3), particularly beyond the age of 14 years.

Ventricular arrhythmias on Holter monitoring or exercise stress testing.12

Imaging Studies:

Echocardiography: May reveal right ventricular enlargement, wall motion abnormalities, and/or aneurysms.12

Cardiac Magnetic Resonance Imaging (MRI): Considered the gold standard for imaging ARVD, MRI can identify right ventricular structural abnormalities, fibrofatty infiltration, and regional wall motion abnormalities.12

Right Ventriculography: A contrast-enhanced imaging modality that can show regional wall motion abnormalities and aneurysms.12

Histopathologic Findings:

Endomyocardial biopsy: Although not routinely performed due to its invasive nature, biopsy can reveal fibrofatty replacement of myocardium, a hallmark of ARVD. Biopsy findings should be interpreted in conjunction with clinical and imaging findings.12

Genetic Testing:

Mutations in genes encoding desmosomal proteins (e.g., PKP2, DSP, DSG2) are found in a significant proportion of ARVD cases. Genetic testing can help confirm the diagnosis and identify at-risk family members.12

It is important to note that the diagnosis of ARVD requires the presence of multiple criteria and should be made by a multidisciplinary team of cardiologists, electrophysiologists, and genetic counselors experienced in the management of inherited cardiac conditions. Early diagnosis and appropriate management are crucial in reducing the risk of sudden cardiac death and improving outcomes in individuals with ARVD.12,13,14.

TREATMENT

The management of Arrhythmogenic Right Ventricular Dysplasia (ARVD) aims to reduce the risk of arrhythmias and sudden cardiac death, alleviate symptoms, and improve quality of life. The treatment approach is individualized based on the severity of the disease, the presence of symptoms, and the risk of arrhythmias. The following are key components of the treatment strategy for ARVD:

Lifestyle Modifications:

Avoidance of competitive sports and strenuous physical activity, especially in individuals at high risk of arrhythmias or sudden cardiac death.15,16

Regular exercise tailored to individual capabilities, under the guidance of a healthcare professional.15,16

Pharmacological Therapy:

Antiarrhythmic medications: Such as beta-blockers or sotalol, may be prescribed to reduce the frequency and severity of ventricular arrhythmias.

Amiodarone: Used in refractory cases or when other antiarrhythmic medications are contraindicated.15,16

Implantable Cardioverter-Defibrillator (ICD) Placement:

Considered in individuals with a history of sustained ventricular arrhythmias, syncope, or high-risk features on risk stratification.15,16

ICDs monitor heart rhythm and deliver a shock to restore normal rhythm if a life-threatening arrhythmia occurs.15,16

Catheter Ablation:

Used to eliminate arrhythmogenic foci or pathways in the heart that are responsible for ventricular arrhythmias.15,16

Particularly useful in individuals with frequent ventricular arrhythmias that are not controlled with medication.15,16

Heart Transplantation:

Considered in individuals with advanced heart failure or refractory arrhythmias that are not amenable to other treatments.15,16

Reserved for severe cases due to the limited availability of donor hearts and the risks associated with transplantation.15,16

Genetic Counseling and Family Screening:

Genetic testing and counseling for affected individuals and their family members to identify genetic mutations and assess the risk of ARVD.15,16

Regular cardiac screening of at-risk family members, including clinical evaluation, ECG, and imaging studies.15,16

Supportive Care:

Management of heart failure symptoms with diuretics, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARBs) as needed.15,16

Psychological support and counseling for individuals and families dealing with the emotional impact of ARVD.17

The management of ARVD requires a multidisciplinary approach involving cardiologists, electrophysiologists, genetic counselors, and other healthcare professionals. Regular follow-up evaluations are essential to monitor disease progression, adjust treatment strategies, and provide ongoing support to affected individuals and their families.18

CONCLUSION

Arrhythmogenic Right Ventricular Dysplasia (ARVD) is a rare but potentially life-threatening cardiac disorder characterized by fibrofatty replacement of the right ventricular myocardium. Despite its rarity, ARVD poses significant challenges in diagnosis and management due to its variable clinical presentation and the absence of a single definitive diagnostic test. The diagnosis of ARVD requires a high index of suspicion and a comprehensive evaluation, including clinical, electrocardiographic, imaging, and histopathologic findings. Genetic testing plays a crucial role in confirming the diagnosis and identifying at-risk family members.

The management of ARVD is multifaceted and involves a combination of lifestyle modifications, pharmacological therapy, implantable cardioverter-defibrillator (ICD) placement, catheter ablation, and, in severe cases, heart transplantation. The goal of treatment is to reduce the risk of arrhythmias and sudden cardiac death, alleviate symptoms, and improve quality of life. Regular follow-up evaluations are essential to monitor disease progression and adjust treatment strategies as needed.

Despite advances in our understanding of ARVD, many aspects of the disease, including its exact prevalence, genetic and environmental triggers, and optimal management strategies, remain incompletely understood. Further research is needed to improve the early detection and management of ARVD, with the ultimate goal of reducing the morbidity and mortality associated with this rare cardiac condition.

REFERENCES

I. Fontaine G, Frank R, Vedel J, Grosgogeat Y, Cabrol C, Facquet J..
Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery. Stimulation studies and epicardial mapping in ventricular tachycardia: study of mechanisms and selection for surgery., pp. 334-350

II. McKoy G, Protonotarios N, Crosby A, Tsatsopoulou A, Anastasakis A, Coonar A, et al.
Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease)..
Lancet. , 355 (2000), pp. 2119-2124 http://dx.doi.org/10.1016/S0140-6736(00)02379-5 |

III. Norgett EE, Hatsell SJ, Carvajal-Huerta L, Cabezas JC, Common J, Purkis PE, et al..
Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma..
Hum Mol Genet. , 9 (2000), pp. 2761-2766

IV. Rampazzo A, Nava A, Malacrida S, Beffagna G, Bauce B, Rossi V, et al..
Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy.
Am J Hum Genet. , 71 (2002), pp. 1200-1206
http://dx.doi.org/10.1086/344208

V. Gerull B, Heuser A, Wichter T, Paul M, Basson CT, McDermott DA, et al..
Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy.Nat Genet. , 36 (2004), pp. 1162-1164 http://dx.doi.org/10.1038/ng1461

VI. Pilichou K, Nava A, Basso C, Beffagna G, Bauce B, Lorenzon A, et al..
Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy..
Circulation. , 113 (2006), pp. 1171-1179
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.583674

VII. Syrris P, Ward D, Evans A, Asimaki A, Gandjbakhch E, Sen-Chowdhry S, et al..
Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2.Am J Hum Genet. , 79 (2006), pp. 978-984
http://dx.doi.org/10.1086/509122

VIII. Heuser A, Plovie ER, Ellinor PT, Grossmann KS, Shin JT, Wichter T, et al. Mutant desmocollin-2 causes arrhythmogenic right ventricular cardiomyopathy..
Am J Hum Genet. , 79 (2006), pp. 1081-1088
http://dx.doi.org/10.1086/509044

IX. Merner ND, Hodgkinson KA, Haywood AF, Connors S, French VM, Drenckhahn JD, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet. , 82 (2008), pp. 809-821
http://dx.doi.org/10.1016/j.ajhg.2008.01.010

X. Van Tintelen JP, Van Gelder IC, Asimaki A, Suurmeijer AJ, Wiesfeld AC, Jongbloed JD, et al. Severe cardiac phenotype with right ventricular predominance in a large cohort of patients with a single missense mutation in the DES gene. Heart Rhythm. , 6 (2009), pp. 1574-1583
http://dx.doi.org/10.1016/j.hrthm.2009.07.041

XI. Tiso N, Stephan DA, Nava A, Bagattin A, Devaney JM, Stanchi F, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet. , 10 (2001), pp. 189-194

XII. Beffagna G, Occhi G, Nava A, Vitiello L, Ditadi A, Basso C, et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res. , 65 (2005), pp. 366-373
http://dx.doi.org/10.1016/j.cardiores.2004.10.005

XIII. Taylor M, Graw S, Sinagra G, Barnes C, Slavov D, Brun F, et al. Genetic variation in titin in arrhythmogenic right ventricular cardiomyopathy-overlap syndromes. Circulation. 124 (2011), pp. 876-885
http://dx.doi.org/10.1161/CIRCULATIONAHA.110.005405

XIV. Quarta G, Syrris P, Ashworth M, Jenkins S, Zuborne Alapi K, Morgan J, et al..

XV. Mutations in the Lamin A/C gene mimic arrhythmogenic right ventricular cardiomyopathy.
Eur Heart J. , (2011),

XVI. McKenna WJ, Thiene G, Nava A, Fontaliran F, Blomstrom-Lundqvist C, Fontaine G, et al.Diagnosis of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Task Force of the Working Group Myocardial and Pericardial Disease of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the International Society and Federation of Cardiology.
Br Heart J. , 71 (1994), pp. 215-218
Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/ dysplasia: proposed modification of the Task Force criteria.. Eur Heart J. , 31 (2010), pp. 806-814
http://dx.doi.org/10.1093/eurheartj/ehq025

XVII. Marcus FI, Fontaine GH, Guiraudon G, Frank R, Laurenceau JL, Malergue C, et al..
Right ventricular dysplasia: a report of 24 adult cases. Circulation. , 65 (1982), pp. 384-398

XVIII. Corrado D, Thiene G, Nava A, Rossi L, Pennelli N. Sudden death in young competitive athletes: clinicopathologic correlations in 22 cases. Am J Med. , 89 (1990), pp. 588-596